Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Transcript of Product
Innovation diffusion issues
Potential R&D cost as new vaccines come out which could affect pricing
Overproduction and limited shelf life
Patent protection and authenticity regulation in developing countries
Currently tested vaccines that can be used:
Herpes Simplex Virus
Low cost product
Penetration pricing strategy
Price of substitutes: $0.5 - $0.6 for syringes
Price of vaccines in market: $15 - $75
production cost of nanopatch: 10 cents
Vaccine used : 0.01% of regular vaccine
Potential overall cost : $1
Potential sales price : under $15
Merck is an International developer, manufacturer and distributor of pharmaceuticals.
Vaxxas is a subsidiary of Merck. It is a venture capital funded technology start-up company developing technology that originated from Professor Mark Kendall's research group at the University of Queensland
The Nanopatch™ approach consists of an array of thousands of vaccine-coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface.
Threat of New Entry
Patent protection offers an extremely high barrier to entry.
Firms wanting to produce generic copies at lower prices must wait for the patent to exipire.
Significant research and development costs (money, time, talents) prohibit smaller firms from quickly entering the market.
Large institutions:hospitals, non-profit organizations, schools' health center
Smaller buyers: clinic, pharmacies.
Penetration and user learning process
The only authority/ agency for promotion
Various Substitutes (needle/needle- free)
We offer: cheaper price, easier storage
Threat of Substitution
- Other needle free drug delivery systems
Highly competitive market, many middle sized suppliers
Large quantities we acquire
Simple and feasible
-Over the last ten years, competition in this segment has grown significantly.
-The leading needle-free drug delivery companies include Antares, Bioject, MediImmune and Zogenix.
-There also exists a number of smaller firms which sometimes partner with large pharmaceutical companies.
Examples include partnerships between Medical House and Doctor Reddy's Laboratories.
10% fear the needle
Children's improved experience
Vaxxas was establsihed in 2011. It raised $15million AUD through a Series A venture financing.
Major investors: OneVentures
Brandon Capital Partners
HealthCare Ventures LLC
The Company Profile
Lower risk of infection
Using less material = less costs, more vaccinations
Uses a lower amount of vaccine with same effect
David Hoey--former vice president of business development at PathoGenetix
Vice President of R&D:
Angus Forster--former consultant with GSK
-Some consumers, espesically those in the late majority and laggards, may be unwilling to adopt such a radically new technology.
-Some may even be willing to accept a conventional needle-based injection rather than taking a risk.
- Major competitiors include the Biojector 2000, the Vitajet, and the Glide system
sizes vary based on dosage
Potential Use for a variety of vaccines
Limited to under skin vaccination
Mass-produced and tested
Growing consumer market
Potential for self-application
Affordable for donation in large scales
Needleless vaccination companies:
Bioject (largest market share)
(Website, search engine)
Managed health care providers
1. Enhance the therapeutic and market potential of existing vaccines
2. Provide unprecedented immunogenic response to enable new, next generation vaccines.
For vaccine companies--
Communicate product through sales representatives
Set up research partnerships to use nanopatch
Introduce the product on medical conferences;
Provide a small amount of free samples to local hospitals (by pharmaceutical representatives)
For other non-profit organizations--
Donate products to the World Health Organization and the American Red Cross.
Sales representatives introduce the product to the pharmacies.
Provide a discount for the first time purchase.
The Nanopatch is smaller than a postage stamp.
It is a one-centimetre-square of silicon, the surface of which has around 20,000 microprojections, all invisible to the naked eye.
Major components are silicon and immune-activating materials
Other vaccine providers
Non profit organizatons
Antares' Pen Injector
Fighting the resistance
Goal: to make the nanopatch professional, high-technological
No cold chain
Goal: to make the nanopatch social-responsible
Long term compatibility
Goal: to make the nanopatch cheap and easy-accessible
Cold chain required
Advertising: TV ads, medical journals, general consumer magazines and newspapers, internet
VACCINE MARKET STRUCTURE 2010
Small size market :
2/3 % of the global pharmaceutical market
Spectacular growth rate :
10-15 % per year versus 5-7 % for Pharmaceuticals
Father of Nanopatch--Mark Kendall
Tripled in value from 5 billion USD in 2000 to almost 24 billion USD in 2013
Global market projected to rise to 100 billion USD by 2025
More than 120 new products in the development pipeline
Newer and more expensive vaccines are coming into the market faster than ever before
Global Vaccine Competitions
4 large multi -national
corporations make up 80% of the globalmarket
Major focus on new vaccine development for industrialised country markets
potential in various target markets with revolutionary product
Government regulation for new vaccines